Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765143 | 0.89 | — | — | |
| SCHEMBL13336989 | 0.88 | CYP3A4 (0.44) | CYP3A4ELANEKCNH2CTSS | |
| SCHEMBL12765151 | 0.85 | CYP3A4 (0.36) | CYP3A4ELANEKCNH2 | |
| SCHEMBL13336902 | 0.81 | ADORA3 (0.41) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL12765136 | 0.81 | CFD (0.41) | — | |
| SCHEMBL12725995 | 0.81 | CYP3A4 (0.45) | CYP3A4ELANEKCNH2 | |
| SCHEMBL13336771 | 0.81 | CYP3A4 (0.50) | CYP3A4ELANEKCNH2 | |
| SCHEMBL7936165 | 0.80 | CYP3A4 (0.48) | CYP3A4ELANEKCNH2 | |
| SCHEMBL13336996 | 0.79 | CYP3A4 (0.36) | CYP3A4ELANEKCNH2CTSS | |
| SCHEMBL7947119 | 0.79 | CYP3A4 (0.47) | CYP3A4ELANEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932277-B2 | Peptide inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297476-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, HDGF, EIF2AK2 | CYP3A4 4436/4885ELANE 365/4885KCNH2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.